Asuragen, microRNA Rx Subsidiary Awarded NIH Grants to Support Rx, Dx-Development | GenomeWeb

By Doug Macron

Asuragen and its subsidiary Mirna Therapeutics this month received nearly $600,000 in grant funding from the National Institutes of Health to fund their respective efforts to develop microRNA-based diagnostics and drugs.

The first grant was awarded to Asuragen researcher Elizabeth Mambo to support her work identifying biomarkers for determining a patient's risk of colon cancer recurrence.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.